Sign In
Buy CLNN
$5.76
-0.110 (-1.87%)
At Close: Jun 03, 2026
FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene's NIH-sponsored Expanded Access Program NfL EAP biomarker analyses to be conducted
Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025
09:00am, Monday, 09'th Jun 2025
SALT LAKE CITY, UT / ACCESS Newswire / June 9, 2025 / Clene Inc. announced that Rob Etherington, Chief Executive Officer and President, will be presenting at the Investor Summit Virtual taking place o
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
10:15am, Wednesday, 07'th May 2025
Clene Inc. (CLNN) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $1.80 per share a year ago.
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
08:00am, Wednesday, 07'th May 2025
Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilamen
Clene to Present at the Emerging Growth Conference
08:30am, Monday, 14'th Apr 2025
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopha
Clene to Present at the Jones Healthcare and Technology Innovation Conference
08:30am, Tuesday, 01'st Apr 2025
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates
10:10am, Monday, 24'th Mar 2025
Clene Inc. (CLNN) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.20 per share a year ago.
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
08:00am, Monday, 24'th Mar 2025
SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage b
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
08:00am, Wednesday, 12'th Mar 2025
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage
Clene to Present at the 37TH Annual Roth Conference
08:30am, Thursday, 06'th Mar 2025
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage b
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11
09:15am, Thursday, 27'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Rob Etherington, CEO, and Morgan Brown, CFO, of Clene Inc., will be presenting at this year's Investor Summit Virtual on March 11th. About Clene In
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers APST Research data includes thousands of people living with ALS including
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
08:30am, Tuesday, 10'th Dec 2024
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bi
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates
09:45am, Wednesday, 13'th Nov 2024
Clene Inc. (CLNN) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $0.40 per share a year ago.
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
08:30am, Monday, 30'th Sep 2024
SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopha
